23 May 2023 | News
DEBx Medical is innovating the management of chronic wounds, improving the life of millions of patients
Image credit: shutterstock
TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, has announced an investment, from its TVM Healthcare Afiyah Fund, of EUR 10 million into DEBx Medical, an Amsterdam-based medical devices company.
DEBx Medical, founded in 2019, has developed a groundbreaking product, DEBRICHEM, which offers a superior alternative to existing treatments for non-healing chronic wounds. This innovative product is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds. With CE and ISO approvals obtained in February 2021, DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market.
Chronic wounds pose a significant healthcare challenge, affecting approximately 2.4% of the population throughout their lifetime, and is particularly pronounced in the Gulf Cooperation Council (GCC) countries, where high levels of diabetes contribute to the problem. Hard-to-heal wounds have the potential for poor patient health and quality of life outcomes and represent a substantial cost to healthcare systems.
TVM Capital Healthcare's investment in DEBx Medical will enable the company to commence commercialisation of its groundbreaking product for the benefit of patients. As part of the firm's investment, DEBx Medical will establish a regional headquarter and a production base in Middle East & North Africa (MENA), thereby accelerating the introduction of its innovative wound care solution to the region.